US-based clinical research organisation Parexel and the Japanese Foundation for Cancer Research (JFCR), the first and leading non-profit cancer research organisation in Japan, have announced a strategic alliance to accelerate access to oncology clinical trials in Japan.  

Under the agreement, JFCR will join Parexel’s Global Site Alliance network, making it a preferred site for oncology clinical trials and providing more opportunities for Japanese patients to participate in cancer research.

Parexel will leverage JFCR's expertise to help sponsors develop protocols that better align with Japan's standard of care and regulatory approval processes, resulting in streamlined patient recruitment and study startup. 

JFCR’s therapeutic expertise in combination with Parexel’s clinical research experience will enable both organisations to efficiently recruit Japanese patients often underrepresented in oncology research while expanding cancer care options in Japan. 

Parexel's strategic alliance agreement with JFCR is an extension of its Patients-First focus and efforts to drive clinical innovation in key therapeutic areas, such as oncology, in the Asia Pacific region. Parexel maintains relationships with other leading alliance sites in the region, including Kyoto University Hospital, Osaka International Cancer Institute, Beijing Illness Challenge Foundation and the Cancer Hospital Chinese Academy of Medical Sciences.